bloom semaglutide research Faces in Bloom- Semaglutide GLP-1 Agonists | Bloom Wellness

By following these steps, patients can enjoy the benefits of GLP-1 RAs while minimizing health risks

1 The results were clear: Semaglutide group: 15.8% average weight loss Liraglutide group: 6.4% average weight loss 70.9% of semaglutide participants lost at least 10% of body weight, compared with 25.6% on liraglutide 55.0% of semaglutide participants lost at least 15%, compared with 12.0% on liraglutide This trial provides the strongest available evidence that Wegovy is substantially more effective than Saxenda for weight loss

Omega-3 fatty acids support hormone production, reduce inflammation, and maintain the health of mucous membranes throughout the body, including vaginal tissue

Tirzepatide did not increase risks of adverse renal events, urinary tract infections, nephrolithiasis (kidney stones), acute kidney injury, or renal cancer compared to placebo, insulin, or other GLP-1 receptor agonists

But after we really see how cost-effective they are, I think insurance companies and the payers will also join us to move forward with these drugs and the new ones in the pipeline